Table 1.
Completed Research Studies and Clinical Trials | |||||
---|---|---|---|---|---|
No. | Study Title | Condition(s) | Intervention(s) | Reference | ClinicalTrials.gov Identifier |
1. | A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors | Refractory solid tumours | Hydralazine and magnesium valproate | [119] | NCT00404508 |
2. | Gene Expression Variation and Implant Wound Healing among Smokers and Diabetics | - Smoking - Diabetes |
Dental implant surgery | [120] | NCT01663298 |
3. | Histone Methyltransferase G9a and H3K9 Dimethylation Inhibit the Self-Renewal of Glioma Cancer Stem Cells | Glioma | Histone methyltransferase G9a and H3K9 dimethylation | [121] | N/A |
4. | Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer | Cervical cancer | Hydralazine and magnesium valproate | [122] | NCT00404326 |
5. | Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors | Cancer | MG98, an oligonucleotide to DNA DNMT1 | [123] | N/A |
6. | Non-Canonical PRC1.1 Targets Active Genes Independent of H3K27me3 and Is Essential for Leukemogenesis | Acute myeloid leukaemia (AML) | Downregulation of non-canonical PRC1.1 complex delays or prevents both carcinogenesis and its development in mice models | [124] | N/A |
7. | Study of Azacitidine in Adult Taiwanese Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) | Myelodysplastic syndromes | Azacitidine | [125] | NCT01201811 |
8. | The Linker Histone H1.0 Generates Epigenetic and Functional Intratumor Heterogeneity | - Breast cancer - Glioma and glioblastoma - Melanoma - Kidney renal papillary cell carcinoma Liver cancer |
Reversible-silencing of linker histone H1.0 to manipulate tumour proliferation | [126] | N/A |
9. | Vidaza to Restore Hormone Thx Prostate | Prostate cancer | Azacitdine for injectable suspension | [127] | NCT00384839 |